Leonard Shelby

[Leonard Shelby @justamelvin]

@MeadowCapital Why would you assume this won't pump on positive ph3 data which is the massive final test. Look at MDGL which was beaten down before ph3 and was still able to pop on ph3 data.

[Leonard Shelby @justamelvin]

@fdzmurillo @KontraInvest @MeadowCapital Clueless. 1. Tirz is still the standard and the only "next gen" drug better is vk2735; 2. Edge is being > than the best obesity drug on the market + less frequent dosing + seamless transition to oral; 3. Dual agonist oral will make current pills obsolete like tirz did to sema

[Leonard Shelby @justamelvin]

@StenAndersen13 @OracleNYSE It's not even better that tirz. Get real.

[Leonard Shelby @justamelvin]

@TheQuantKitty @OracleNYSE Mildly? It underperformed against tirz, which itself underperforms against VK2735. They're a couple levels below from efficacy/tolerability/flexibility standpoint. Not even talking about the fact the oral is the only dual agonist and will render the current pills obsolete.

[Leonard Shelby @justamelvin]

@bioinvestor24 @SteveWagsInvest @NitwitOnFinTwit @Andre_AGTC This is correct. If they didn't raise, they hd cash through the SQ and oral ph3, but not much runway beyond that. The funding overhang would have looked more dire in the next two quarters so it is better to have that cash already on hand.

[Leonard Shelby @justamelvin]

@Rag59326331 Burn rate was exaggerated with trial related costs and initiation, so that's not accurate moving forward. They had enough to fund both ph3 trials through to completion already but this 400 basically allows them runway after the trials are complete.

[Leonard Shelby @justamelvin]

@MAugusterfer @Pharmdca Who needs to? Just 5% of market already gets VKTX to many, many multiples of current price. More than that is just gravy. A lot gravy.

[Leonard Shelby @justamelvin]

@tradingbios @murphycpr @AppleHelix @STL_Biotech They have been on sale, but not at a discount. They've been asking for what Bourla called "crazy demands." The question is will the data push someone to meet the ask. If not, they can aim to capture 5% of the market and be worth many many multiples in a few years.

[Leonard Shelby @justamelvin]

@bioinvestor24 @GilaMonstrum Not sure how much ignorance there is after today with pretty clear data. Historically, the company has popped huge on good data until about 2 years ago. Huge pop within a year is inevitable at this point, though.

[Leonard Shelby @justamelvin]

@GilaMonstrum @bioinvestor24 Lots of manipulation at play on a hyped name like this.

[Leonard Shelby @justamelvin]

@MeadowCapital @Icculus13 Yes, I agree, if not clean, reaction can go in many ways.

[Leonard Shelby @justamelvin]

@Icculus13 @MeadowCapital Obesity week 24 was the only time that happened because data drop was telegraphed for shorts. Oral ph2 data was obscured by poor trial design and pill burden, so reaction was expected from market looking for clean data after ph1. Bottom line is new data needs to be clean.

[Leonard Shelby @justamelvin]

@wallstlobo @felandostephen1 @biotech_bullet Reality is MASH drug doesn't have much standalone value. Also, data isn't likely out for at least another 1-2 weeks so there's time yet for a runup, but lack of run up is far from a bad thing.

[Leonard Shelby @justamelvin]

@keylimepieco @meangenebio @brwtoovey Right. Also, this small molecule hype based purely on cost ignores how consumer driven the market is. Vk2735 is likely head and shoulders above any small molecule on efficacy/tolerability, but muddy oral ph2 trial obscured that. Fantastic value for smart forward looking investors

[Leonard Shelby @justamelvin]

@TheBioMAHunter @HarpA70278288 @PersimmonTI I suppose there's an outside chance out of desperation, but I'm skeptical they suddenly see the light after such (mostly obvious) bad acquisitions. I think NVO should be just as desperate and has deeper pockets.

[Leonard Shelby @justamelvin]

@ShmuelLon @RoniVeredAdar Y'all need to do more DD lmao.

[Leonard Shelby @justamelvin]

@TheBioMAHunter @HarpA70278288 @PersimmonTI Zero chance after wasting 10b on MTSR.

[Leonard Shelby @justamelvin]

@bioinvestor24 I am optimistic but I would caution reading too much into BL's comments. Sometimes he gives hints, and sometimes he really hasn't looked at data (he seemed caught off guard by aspects of ph2 oral data for example). We'll see

[Leonard Shelby @justamelvin]

@breakoutchrts @cigs1234 @HarpA70278288 You're both right. But I think the point traderider is making is that lower start will help offset a higher/rapid titration scheme to some extent. It's just a guess as to how much, but I have been of the mind we won't see AEs significantly above those from the 15mg arm in ph2.

[Leonard Shelby @justamelvin]

@Placeb0HQ @breakoutchrts You don't think lower dose offsets to solve extent the rapid titration? 15mg arm in ph2 started at 5mg and it'll take take probably 2 steps in the maintenance before it reaches that level. I think we could see slightly higher AEs than ph2, but not much more.